Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 263

1.

Is ranolazine an antiarrhythmic drug?

Eckhardt LL, Teelin TC, January CT.

Am J Physiol Heart Circ Physiol. 2008 May;294(5):H1989-91. doi: 10.1152/ajpheart.00285.2008. Epub 2008 Mar 28. No abstract available.

2.

An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes.

Song Y, Shryock JC, Belardinelli L.

Am J Physiol Heart Circ Physiol. 2008 May;294(5):H2031-9. doi: 10.1152/ajpheart.01357.2007. Epub 2008 Feb 29.

3.

Potential application of late sodium current blockade in the treatment of heart failure and atrial fibrillation.

Doshi D, Morrow JP.

Rev Cardiovasc Med. 2009;10 Suppl 1:S46-52. Review.

PMID:
19898288
4.

Enhanced late na(+) currents in atrial fibrillation new drug target or just an epiphenomenon?

Schotten U, Verheule S, Kerfant BG, Greiser M.

J Am Coll Cardiol. 2010 May 25;55(21):2343-5. doi: 10.1016/j.jacc.2010.01.046. No abstract available.

5.

Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.

Fredj S, Sampson KJ, Liu H, Kass RS.

Br J Pharmacol. 2006 May;148(1):16-24.

6.

A slowly inactivating sodium current contributes to spontaneous diastolic depolarization of atrial myocytes.

Song Y, Shryock JC, Belardinelli L.

Am J Physiol Heart Circ Physiol. 2009 Oct;297(4):H1254-62. doi: 10.1152/ajpheart.00444.2009. Epub 2009 Aug 21.

7.
8.

A focus on antiarrhythmic properties of ranolazine.

Vizzardi E, D'Aloia A, Quinzani F, Bonadei I, Rovetta R, Bontempi L, Curnis A, Dei Cas L.

J Cardiovasc Pharmacol Ther. 2012 Dec;17(4):353-6. doi: 10.1177/1074248412442000. Epub 2012 Apr 6. Review.

PMID:
22492919
9.
10.

Pathophysiology and pharmacology of the cardiac "late sodium current.".

Zaza A, Belardinelli L, Shryock JC.

Pharmacol Ther. 2008 Sep;119(3):326-39. doi: 10.1016/j.pharmthera.2008.06.001. Epub 2008 Jul 1. Review.

PMID:
18662720
11.

Late sodium current inhibition as a new cardioprotective approach.

Hale SL, Shryock JC, Belardinelli L, Sweeney M, Kloner RA.

J Mol Cell Cardiol. 2008 Jun;44(6):954-67. doi: 10.1016/j.yjmcc.2008.03.019. Epub 2008 Apr 8. Review.

PMID:
18462746
12.

A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias.

Belardinelli L, Liu G, Smith-Maxwell C, Wang WQ, El-Bizri N, Hirakawa R, Karpinski S, Li CH, Hu L, Li XJ, Crumb W, Wu L, Koltun D, Zablocki J, Yao L, Dhalla AK, Rajamani S, Shryock JC.

J Pharmacol Exp Ther. 2013 Jan;344(1):23-32. doi: 10.1124/jpet.112.198887. Epub 2012 Sep 25.

13.

The antiarrhythmic effects of ranolazine.

Foster NJ, Haines DE.

Rev Cardiovasc Med. 2009;10 Suppl 1:S38-45. Review.

PMID:
19898287
14.

Ranolazine: an antianginal drug with antiarrhythmic properties.

Tamargo J, Caballero R, Delpón E.

Expert Rev Cardiovasc Ther. 2011 Jul;9(7):815-27. doi: 10.1586/erc.11.91. Review.

PMID:
21809962
15.

Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes.

Song Y, Shryock JC, Wu L, Belardinelli L.

J Cardiovasc Pharmacol. 2004 Aug;44(2):192-9.

PMID:
15243300
16.

Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation.

Sossalla S, Wagner S, Rasenack EC, Ruff H, Weber SL, Schöndube FA, Tirilomis T, Tenderich G, Hasenfuss G, Belardinelli L, Maier LS.

J Mol Cell Cardiol. 2008 Jul;45(1):32-43. doi: 10.1016/j.yjmcc.2008.03.006. Epub 2008 Mar 14.

PMID:
18439620
17.

Mechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: insights from mathematical models and experimental correlates.

Comtois P, Sakabe M, Vigmond EJ, Munoz M, Texier A, Shiroshita-Takeshita A, Nattel S.

Am J Physiol Heart Circ Physiol. 2008 Oct;295(4):H1489-504. doi: 10.1152/ajpheart.01054.2007. Epub 2008 Aug 1.

18.

Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation.

Verrier RL, Kumar K, Nieminen T, Belardinelli L.

Europace. 2013 Mar;15(3):317-24. doi: 10.1093/europace/eus380. Epub 2012 Dec 7. Review.

19.

Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure.

Burashnikov A, Di Diego JM, Barajas-Martínez H, Hu D, Cordeiro JM, Moise NS, Kornreich BG, Belardinelli L, Antzelevitch C.

Circ Heart Fail. 2014 Jul;7(4):627-33. doi: 10.1161/CIRCHEARTFAILURE.114.001129. Epub 2014 May 29. Erratum in: Circ Heart Fail. 2015 Jul;8(4):841. Zygmunt, Andy [removed].

20.

Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol.

Burashnikov A, Pourrier M, Gibson JK, Lynch JJ, Antzelevitch C.

Circ Arrhythm Electrophysiol. 2012 Apr;5(2):400-8. doi: 10.1161/CIRCEP.111.968305. Epub 2012 Feb 9.

Supplemental Content

Support Center